Array BioPharma (ARRY) PT Raised to $35 at Piper Jaffray

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Array BioPharma (ARRY) PT Raised to $35 at Piper Jaffray

Array Biopharma (ARRY) PT Set at Street High of $37 at Wells Fargo, Guggenheim - Bloomberg

May 21, 2019 2:23 PM EDT

Array Biopharma (NASDAQ: ARRY) PT Set at Street High of $37 at Wells Fargo, Guggenheim - Bloomberg

... More

Buy Array BioPharma (ARRY) On Weakness Surrounding Triplet Data - Stifel

May 21, 2019 9:32 AM EDT

Stifel analyst Stephen Willey reiterated a Buy rating and $29.00 price target on Array BioPharma (NASDAQ: ARRY) after the company announced long-awaited interim top-line results from the P3 BEACON trial evaluating the combination of BRAFTOVI/MEKTOVI/cetuximab (triplet) vs. combinations of both BRAFTOVI/cetuximab (doublet) and... More

Array Biopharma (ARRY) Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial

May 21, 2019 8:01 AM EDT

Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor, and ERBITUX® (cetuximab), an anti-EGFR antibody (BRAFTOVI Triplet), in patients with... More